Cargando…

Dual‐Specificity Phosphatase 26 Protects Against Cardiac Hypertrophy Through TAK1

BACKGROUND: Heart pathological hypertrophy has been recognized as a predisposing risk factor for heart failure and arrhythmia. DUSP (dual‐specificity phosphatase) 26 is a member of the DUSP family of proteins, which has a significant effect on nonalcoholic fatty liver disease, neuroblastoma, glioma,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Jing, Jiang, Xiaoli, Liu, Jinhua, Ye, Ping, Jiang, Lang, Chen, Manhua, Xia, Jiahong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955340/ https://www.ncbi.nlm.nih.gov/pubmed/33522247 http://dx.doi.org/10.1161/JAHA.119.014311

Ejemplares similares

Dual-specificity Phosphatase 9 protects against Cardiac Hypertrophy by targeting ASK1
por: Jiang, Lang, et al.
Publicado: (2021)

Dual‐Specificity Phosphatase 26 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through Transforming Growth Factor Beta–Activated Kinase 1 Suppression
por: Ye, Ping, et al.
Publicado: (2019)

Dual‐Specificity Phosphatase 9 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through ASK1 Suppression
por: Ye, Ping, et al.
Publicado: (2018)

SWAP70 Overexpression Protects Against Pathological Cardiac Hypertrophy in a TAK1‐Dependent Manner
por: Qian, Qiaofeng, et al.
Publicado: (2023)

ADAM23 in Cardiomyocyte Inhibits Cardiac Hypertrophy by Targeting FAK‐AKT Signaling
por: Xiang, Mei, et al.
Publicado: (2018)

The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling
por: Ji, Yan-Xiao, et al.
Publicado: (2016)

Arginyltransferase knockdown attenuates cardiac hypertrophy and fibrosis through TAK1-JNK1/2 pathway
por: Singh, Kanika, et al.
Publicado: (2020)

Sanggenon C protects against pressure overload-induced cardiac hypertrophy via the calcineurin/NFAT2 pathway
por: Xiao, Lili, et al.
Publicado: (2017)

Tomoregulin-1 prevents cardiac hypertrophy after pressure overload in mice by inhibiting TAK1-JNK pathways
por: Bao, Dan, et al.
Publicado: (2015)

Ubiquitin‐specific protease 19 blunts pathological cardiac hypertrophy via inhibition of the TAK1‐dependent pathway
por: Miao, Rujia, et al.
Publicado: (2020)

Author Correction: Arginyltransferase knockdown attenuates cardiac hypertrophy and fibrosis through TAK1-JNK1/2 pathway
por: Singh, Kanika, et al.
Publicado: (2020)

Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway
por: Liao, Hai-han, et al.
Publicado: (2019)

Slowing Heart Rate Protects Against Pathological Cardiac Hypertrophy
por: Sebastian, Sonia, et al.
Publicado: (2022)

ICS II protects against cardiac hypertrophy by regulating metabolic remodelling, not by inhibiting autophagy
por: Han, Dongjian, et al.
Publicado: (2020)

Oridonin protects against cardiac hypertrophy by promoting P21-related autophagy
por: Xu, Man, et al.
Publicado: (2019)

The Toll-like receptor 4 antagonist TAK-242 protects against chronic pancreatitis in rats
por: Pan, Long-Fei, et al.
Publicado: (2017)

GCN5-mediated regulation of pathological cardiac hypertrophy via activation of the TAK1-JNK/p38 signaling pathway
por: Li, Jia, et al.
Publicado: (2022)

Protective effect of hydrogen sulphide against myocardial hypertrophy in mice
por: Shao, Mingjing, et al.
Publicado: (2017)

Choline Protects Against Cardiac Hypertrophy Induced by Increased After-load
por: Zhao, Yilei, et al.
Publicado: (2013)

SIRT2 inhibition protects against cardiac hypertrophy and ischemic injury
por: Yang, Xiaoyan, et al.
Publicado: (2023)

TAK-242, a Toll-Like Receptor 4 Antagonist, Protects against Aldosterone-Induced Cardiac and Renal Injury
por: Zhang, Yide, et al.
Publicado: (2015)

Protections of transcription factor BACH2 and natural product myricetin against pathological cardiac hypertrophy and dysfunction
por: Jiang, Xueli, et al.
Publicado: (2022)

APJ ACTS AS A DUAL RECEPTOR IN CARDIAC HYPERTROPHY
por: Scimia, Maria Cecilia, et al.
Publicado: (2012)

Zinc-finger protein 418 overexpression protects against cardiac hypertrophy and fibrosis
por: Pan, Liming, et al.
Publicado: (2017)

H(2)S Protects against Cardiac Cell Hypertrophy through Regulation of Selenoproteins
por: Greasley, Adam, et al.
Publicado: (2019)

Glucosylceramide synthase inhibition protects against cardiac hypertrophy in chronic kidney disease
por: Baccam, Gabriel C., et al.
Publicado: (2022)

Angiotensin‐Converting Enzyme 3 (ACE3) Protects Against Pressure Overload‐Induced Cardiac Hypertrophy
por: Yu, Chang‐Jiang, et al.
Publicado: (2016)

Cardiac LXRα protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization
por: Cannon, Megan V, et al.
Publicado: (2015)

CYP2J2 Overexpression Protects against Arrhythmia Susceptibility in Cardiac Hypertrophy
por: Westphal, Christina, et al.
Publicado: (2013)

Testin protects against cardiac hypertrophy by targeting a calcineurin‐dependent signalling pathway
por: Gao, Lu, et al.
Publicado: (2018)

Transmembrane protein 117 knockdown protects against angiotensin-II-induced cardiac hypertrophy
por: Yang, Yi, et al.
Publicado: (2023)

Dual-Specificity Phosphatases in Immunity and Infection: An Update
por: Lang, Roland, et al.
Publicado: (2019)

POPX2 phosphatase regulates apoptosis through the TAK1-IKK-NF-κB pathway
por: Weng, Ting, et al.
Publicado: (2017)

Aerobic exercise protects against pressure overload-induced cardiac dysfunction and hypertrophy via β3-AR-nNOS-NO activation
por: Wang, Bin, et al.
Publicado: (2017)

Expression and regulation of type 2A protein phosphatases and alpha4 signalling in cardiac health and hypertrophy
por: Eleftheriadou, Olga, et al.
Publicado: (2017)

Tanshinone IIA Protects Against Cardiac Hypertrophy via Inhibiting Calcineurin/Nfatc3 Pathway
por: Tan, Xueying, et al.
Publicado: (2011)

Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway
por: Cai, Jun, et al.
Publicado: (2010)

Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway
por: Cai, Jun, et al.
Publicado: (2009)

HMGB1 Is Involved in the Protective Effect of the PPARα Agonist Fenofibrate against Cardiac Hypertrophy
por: Jia, Zhankui, et al.
Publicado: (2014)

Andrographolide Protects against Aortic Banding-Induced Experimental Cardiac Hypertrophy by Inhibiting MAPKs Signaling
por: Wu, Qing Q., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ql0c7hkv0ln8jmoa4nmir8m2io